SCHEMBL10285459

SCHEMBL10285459

CCc1ccc2c(c1)NCN2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.42
TRPA1 O75762 1/20 0.40
ALDH1A1 P00352 3/20 0.40
GAA P10253 2/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2A6 P11509 1/20 0.39
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
DRD1 P21728 1/20 0.38
ADRA1D P25100 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
HTR3A P46098 1/20 0.38
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19805956 0.87 KDM4E (0.44) PARP1TRPA1ALDH1A1GAAHPGD
SCHEMBL23519530 0.83 HTR1A (0.43) HTR1ADRD2DRD1ADRA1DHTR2A
SCHEMBL3370237 0.79 ESR1 (0.43) ALDH1A1KDM4EHTR2AHTR2CLMNA
SCHEMBL17195712 0.78 HTR1A (0.38) GAACYP2A6HTR1ADRD2DRD1
SCHEMBL19346233 0.78 GABRA1 (0.43) ALDH1A1HPGDKDM4ECYP1A2HTR1A
SCHEMBL18657127 0.77 SMN1; SMN2 (0.47) PARP1TRPA1ALDH1A1GAAHPGD
SCHEMBL13266636 0.75 CA12 (0.43) PARP1TRPA1ALDH1A1GAAHPGD
SCHEMBL8201000 0.74 PARP1 (0.54) PARP1ALDH1A1GAAHPGDKDM4E
SCHEMBL15624185 0.74 PARP1 (0.36) PARP1TRPA1ALDH1A1GAAHPGD
SCHEMBL19300243 0.74 PARP1 (0.54) PARP1ALDH1A1GAAHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168070-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2021-11-09 US disclosed
US-20200399244-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-12-24 US disclosed
EP-2970224-B1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS INC (US) 2017-09-06 EP disclosed
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES PIGS, GPR174, GPR17 PARP1 3474/4885TRPA1 757/4885ALDH1A1 1098/4885
US-20200399244-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC3 PARP1 301/4885TRPA1 3160/4885ALDH1A1 2185/4885
US-11168070-B2 Therapeutic compounds and uses thereof EP300, HDAC1, HDAC11 PARP1 273/4885TRPA1 2938/4885ALDH1A1 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.